Trial Profile
Efficacy and safety of bevacizumab plus gefitinib as maintenance therapy in patients with non-squamous non-small cell lung cancer patients
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Jun 2016 New trial record